Insider Transactions in Q1 2024 at Natera, Inc. (NTRA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.25%
|
$82,260
$90.42 P/Share
|
|
Mar 28
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,662
-1.12%
|
$239,580
$90.42 P/Share
|
|
Mar 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
464
-0.41%
|
$41,760
$90.42 P/Share
|
|
Mar 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
707
-0.36%
|
$63,630
$90.42 P/Share
|
|
Mar 28
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
743
-0.36%
|
$66,870
$90.42 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.71%
|
$90,000
$90.13 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
447
-0.06%
|
$40,230
$90.27 P/Share
|
|
Mar 27
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,292
+3.05%
|
-
|
|
Mar 27
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,184
+2.14%
|
-
|
|
Mar 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,364
+0.66%
|
-
|
|
Mar 27
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
447
+0.13%
|
-
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Indirect |
50,910
-56.93%
|
$4,480,080
$88.85 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
83,223
-9.68%
|
$7,323,624
$88.86 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
68,270
+7.22%
|
$1,297,130
$19.58 P/Share
|
|
Mar 15
2024
|
Roelof Botha |
BUY
Exercise of conversion of derivative security
|
Direct |
19,924
+15.53%
|
$896,580
$45.64 P/Share
|
|
Mar 07
2024
|
Jonathan Sheena |
BUY
Bona fide gift
|
Indirect |
110,854
+44.16%
|
-
|
|
Mar 07
2024
|
Jonathan Sheena |
SELL
Bona fide gift
|
Direct |
110,854
-24.17%
|
-
|
|
Mar 06
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
5,000
-0.54%
|
$440,000
$88.79 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
190,000
-4.79%
|
$16,720,000
$88.1 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,012
-0.05%
|
$88,044
$87.81 P/Share
|
|
Mar 05
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
1,838
-0.8%
|
$159,906
$87.86 P/Share
|
|
Mar 05
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
2,245
-0.56%
|
$195,315
$87.85 P/Share
|
|
Mar 05
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,826
-3.85%
|
$248,688
$88.36 P/Share
|
|
Mar 05
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,326
-3.64%
|
$820,688
$88.36 P/Share
|
|
Mar 05
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,160
-1.05%
|
$190,080
$88.36 P/Share
|
|
Mar 05
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
1,028
-0.22%
|
$90,464
$88.36 P/Share
|
|
Mar 01
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,400
+2.12%
|
-
|
|
Mar 01
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
2,329
+1.17%
|
-
|
|
Mar 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,826
+3.7%
|
-
|
|
Mar 01
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
9,326
+3.51%
|
-
|
|
Mar 01
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,160
+1.04%
|
-
|
|
Mar 01
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
4,104
+0.38%
|
-
|
|
Mar 01
2024
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
1,028
+0.22%
|
-
|
|
Feb 29
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,607
+3.05%
|
-
|
|
Feb 29
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
3,206
+1.57%
|
-
|
|
Feb 29
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
10,000
-0.53%
|
$870,000
$87.24 P/Share
|
|
Feb 29
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
6,000
-16.99%
|
$540,000
$90.01 P/Share
|
|
Feb 29
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,526
-2.33%
|
$1,785,762
$87.34 P/Share
|
|
Feb 29
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,526
+8.37%
|
$184,734
$9.29 P/Share
|
|
Feb 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
35,307
-14.74%
|
$2,648,025
$75.09 P/Share
|
|
Feb 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
35,307
+6.88%
|
$317,763
$9.85 P/Share
|
|
Feb 23
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Indirect |
380,036
+26.57%
|
$760,072
$2.66 P/Share
|
|
Feb 16
2024
|
Herm Rosenman |
SELL
Open market or private sale
|
Direct |
93,901
-37.03%
|
$6,479,169
$69.47 P/Share
|
|
Feb 16
2024
|
Herm Rosenman |
BUY
Exercise of conversion of derivative security
|
Direct |
93,901
+37.64%
|
$187,802
$2.66 P/Share
|
|
Feb 07
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
5,000
-1.04%
|
$350,000
$70.1 P/Share
|
|
Feb 07
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-2.75%
|
$70,000
$70.1 P/Share
|
|
Feb 06
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
34,029
-32.51%
|
$2,382,030
$70.03 P/Share
|
|
Feb 06
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
34,029
+14.86%
|
$476,406
$14.49 P/Share
|
|
Feb 06
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
6,000
-14.18%
|
$420,000
$70.0 P/Share
|
|
Feb 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,281
-23.98%
|
$1,492,827
$67.73 P/Share
|